“`html
Brainlab IPO Aims to Revolutionize Healthcare Digitization on Frankfurt stock Exchange
Table of Contents
Munich, Germany – June 12, 2025 – Brainlab AG is poised to transform the digital healthcare landscape with its upcoming Initial Public Offering (IPO) on the Frankfurt Stock Exchange [2]. The company intends to raise capital to fuel its expansion and further its “software-first” strategy in the medical technology sector [1].
Brainlab’s IPO Details and Objectives
The IPO, expected in the second half of 2025, could value Brainlab at approximately EUR 2 billion (USD 2.1 billion) [3]. Brainlab aims to utilize the raised capital to accelerate profitable growth and expand its digital ecosystem.
Did You Know? Brainlab solutions are currently used in approximately 4,000 clinics worldwide, impacting over 22 million patients across 120 countries.
Software-Centered Approach and Platform Strategy
Brainlab distinguishes itself from traditional medical technology companies through its software-centered approach. This strategy positions the company as an enabler of interoperable and fully integrated workflows in both surgery and radiation therapy.Stefan Vilsmeier, founder and majority shareholder, emphasized that Brainlab’s vision of a digital, efficient, and patient-centered ecosystem aligns perfectly with the current market habitat.
The company’s platforms, including Loop-X, Cirq, and Exactrac, form a continuous technology infrastructure with scalability that extends beyond its core areas. CEO Rainer Birkenbach noted that Brainlab is currently only addressing a fraction of the clinical applications possible with its technologies.
Expansion into New Clinical Areas
Looking ahead, Brainlab plans to expand into adjacent segments such as orthopedics, sports medicine, ENT (ear, nose, and throat), and cardiovascular interventions.The company also intends to expand its sales network, test market entry into outpatient surgical centers, and strengthen its balance sheet. Strategic partnerships with established players like Boston Scientific and Carl zeiss are expected to broaden the reach and relevance of the Brainlab ecosystem.
Financial Performance and Growth Projections
Brainlab has demonstrated strong growth dynamics, with sales increasing from EUR 364 million in 2021/22 to EUR 470 million in 2023/24, representing an average annual growth of 13.6%. Gross profit also climbed to EUR 294 million during the same period, with a compound annual growth rate (CAGR) of 16.6%, resulting in a margin of 62
